Liatermin
From PeptidePlaza, the free peptide reference · Entry #1206 · Nootropic · Sources fetched 2026-09-11 · Editorial standards
Liatermin is a nootropic research peptide. Liatermin is a GDNF family receptor alpha-1 agonist currently in Phase 2 clinical trials.
Liatermin is a synthetic peptide that acts as an agonist for the GDNF family receptor alpha-1. This mechanism of action suggests its potential in conditions where GDNF signaling is implicated. It has been investigated for its role in Parkinson's Disease, reaching Phase 1 clinical trials for this indication. Research into Liatermin includes randomized controlled trials exploring intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease.
1 Mechanism of action
GDNF family receptor alpha-1 agonist (agonist)
Primary targets: GDNF family receptor alpha-1
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Parkinson Disease
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | GDNF family receptor alpha-1 |
4 Research studies (1)
- Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
Annals of neurology (2006) · RCT
5 Safety and risk profile
5.1 Regulatory status
Liatermin is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Liatermin?
- Liatermin is a synthetic peptide that functions as an agonist for the GDNF family receptor alpha-1. It is currently undergoing clinical development.
- How does Liatermin work?
- Liatermin works by acting as an agonist for the GDNF family receptor alpha-1. This means it binds to and activates this specific receptor, mimicking the effects of its natural ligand.
- What is Liatermin studied for?
- Liatermin has been studied for its potential in treating Parkinson's Disease, where it has reached Phase 1 clinical trials. Its mechanism of action suggests a role in conditions related to GDNF signaling.
- What is the regulatory status of Liatermin?
- Liatermin is currently in Phase 2 clinical trials. It has previously reached Phase 1 for the indication of Parkinson's Disease.
7 References
- Liatermin — molecule record ChEMBL. View source
- Liatermin — published literature (1 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Liatermin.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also nootropic
A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Also nootropic
A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).
Also nootropic
Eptifibatide is an integrin alpha-IIb/beta-3 inhibitor used to decrease the rate of death or myocardial infarction in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention.